


**SUPPLEMENTARY FIGURES**  
**Supplementary Figure 1**




**Supplementary Figure 2**

Prph2	1	<u>..MA-LLKVKFDQKKRVKLAQGLWLMNWLSVLAGIVLFSLGLFLKIELRKRSEVMNNS-ESH</u>	
Rom1	1	<u>MAPVLPVVLPLQPRIRLAQGIWLLSWLLALVGGLTLLCSGHLVQLGHLGTFLAPSCSFP</u>	
RRCT	1	<u>MAPVLPVVLPLQPRIRLAQGIWLLSWLLALVGGLTLLCSGHLVQLGHLGTFLAPSCSFP</u>	
		————— TM1	
Prph2	58	<u>FVPNSLIGVGVLSCVFNFLAGKICYDALDPAKYAKWKPWLKPYLAVCIF-FNVILFLVAL</u>	
Rom1	61	<u>ALPQTALAAGTVALGTGLGGAGASRASLDAAQYPPWRGVLTPLLAVGTAAGGGLLTLALG</u>	
RRCT	61	<u>ALPQTALAAGTVALGTGLGGAGASRASLDAAQYPPWRGVLTPLLAVGTAAGGGLLTLALG</u>	
		————— TM2	————— TM3
Prph2	117	<u>CCFLLRGSLESTLAYGLKNGMKYYRDTDTPGRCFMKKTIDMLQIEFKCCGNNGFRDWFEI</u>	
Rom1	121	<u>LALALPVSLNQGLEEGLEAALAHYKDTEVPGRCQAKRLMDELQLRYHCCGRHGKDFWFGV</u>	
RRCT	121	<u>LALALPVSLNQGLEEGLEAALAHYKDTEVPGRCQAKRLMDELQLRYHCCGRHGKDFWFGV</u>	
Prph2	177	<u>QWISNRYLDFSSKEVKDRIKSNVDGRYLVDGVVFPSCCNPSSPRPCIQYQLTNNSAHYSYD</u>	
Rom1	181	<u>QWVSNRYLDPDSDQDVVDRIQSNVEGLYLIDGVVFPSCCNPHSPRPCLQSQLSDPYAHPLFD</u>	
RRCT	181	<u>QWVSNRYLDPDSDQDVVDRIQSNVEGLYLIDGVVFPSCCNPHSPRPCLQSQLSDPYAHPLFD</u>	
Prph2	237	<u>HQTEELNLWLRGCRAALLNYYSSLMNSMGVVTLVWLFVVSITAGLRYLHTALESVSNPE</u>	
Rom1	241	<u>PRQPNLNLWAQGCHEVLLLEHLQGLSGTLGSILAVTLLLQILVLLGLRYLQTALEGLGGVI</u>	
RRCT	241	<u>PRQPNLNLWAQGCHEVLLLEHLQGLSGTLGSILAVTLLLQILVLLGLRYLHTALESVSNPE</u>	
		————— TM4	
Prph2	297	DPECESEGWLLEKSVPETWKAFLESFKKLGKSNQVEAEGADAGPAPEAG	346
Rom1	301	DGEGEAQGYLFPGGLKDILKTAWLQGGLAHKPAPEEAPPDEEPPKEVLAEA	351
RRCT	301	DPECESEGWLLEKSVPETWKAFLESFKKLGKSNQVEAEGADAGPAPEAG	349

**Supplementary Figure 2. Alignment of Prph2, Rom1, and RRCT peptide sequences.** Text color indicates changing exon. Underlined Prph2 sequence is replaced with Rom1 sequence in the RRCT allele. TM1-4 indicate the transmembrane regions. Prph2 has a predicted molecular weight of 39.2 kDa (without including glycan), Rom1 has a predicted molecular weight of 37.2 kDa (not glycosylated), and RRCT has a predicted molecular weight of 37.3 kDa (not glycosylated). Yellow is the RDS-D2 epitope. Blue is the hypothetical longer peptide for Rom1 2H5, italics is the hypothetical shorter peptide for 2H5.


## Supplementary Figure 3



## Supplementary Figure 3. Expression of RRCT in transfected cells.

**A.** COS-7 cells were transiently transfected with Prph2 constructs (either WT or C214S), RRCT, or Rom1 as indicated above each panel. Cells were labeled for Prph2/RRCT (RDS-CT) or Rom1 in red, calreticulin in green, and DAPI in blue. Images captured at 100x, scale bar: 10  $\mu$ m. **B.** COS-7 cells were transiently transfected with Prph2 and/or RRCT in amounts listed above the blots. Cell lysates were collected and separated on reducing SDS-PAGE. Resultant blots were probed for Prph2/RRCT (RDS-CT) or RRCT (mAB 2H5), with actin as a control.

## Supplementary Figure 4




**Supplementary Figure 4. RRCT alone cannot support OS formation while expression of RRCT and WT Prph2 results in accumulation of abnormal vesicular structures.**

**A.** Shown are representative P30 EM images collected at 15,000x. Scale bars 2µm **B.** Rod and cone OSs were identified by immunogold labeling with rhodopsin (Fliesler polyclonal), and S-

opsin (Craft polyclonal) antibodies, respectively (captured at 50,000x). Arrows highlight immunogold particles using the S-opsin antibodies. Scale bars 500nm **C.** Shown are representative P30 EM images collected at 40,000x. Scale bars 500nm **D.** Rod OSs were identified by immunogold labeling with rhodopsin (Fliesler polyclonal) while cone OSs were identified by labeling with S-opsin (Craft polyclonal) antibodies (captured at 25,000x or 30,000x). Arrows indicate vesicular structures largely lacking labeling for rhodopsin and S-opsin. Scale bars 500nm **E.** Rom1/RRCT was largely localized to vesicular structures (arrowheads), identified using mAB 2H5. Images captured at 50,000x. Scale bars 500nm. **F.** Shown are representative EM images captured at 40,000x (images are the same as those presented in Figure 6 for illustrative purposes). A selection of rims has been traced in red to show variations in pinching seen both between and within genotypes. A selection of outer rim diameters have been labeled in green with inner rim diameters labeled in blue. Scale bar 500 nm.

## Supplementary Figure 5



**Supplementary Figure 5. RRCT protein retains the ability to bind Prph2 and Rom1 *in vitro*.** COS7 cells were double transfected with the constructs indicated at the top of each section. **A.** IP was performed for Prph2 (RDS-D2), and blots were probed for Prph2 (mAB 2B7) and Rom1 (mAB 2H5). **B.** IP was performed for RRCT (RDS-CT), and blots were probed for RRCT (mAB 2B7) and Rom1 (ROM1-CT). **C.** IP was performed for Prph2 (RDS-D2) and blots were probed for Prph2 (RDS-D2) and RRCT (mAB 2H5). I: input, P: preclear, B: bound, U: unbound.